Zacks: Analysts Anticipate Deciphera Pharmaceuticals Inc (DCPH) Will Post Earnings of -$0.66 Per Share
Equities analysts forecast that Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) will announce ($0.66) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Deciphera Pharmaceuticals’ earnings, with estimates ranging from ($0.74) to ($0.60). Deciphera Pharmaceuticals posted earnings of ($0.62) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 6.5%. The business is scheduled to announce its next earnings results on Wednesday, March 27th.
On average, analysts expect that Deciphera Pharmaceuticals will report full year earnings of ($2.59) per share for the current year, with EPS estimates ranging from ($2.70) to ($2.47). For the next fiscal year, analysts anticipate that the company will report earnings of ($2.97) per share, with EPS estimates ranging from ($3.21) to ($2.57). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Deciphera Pharmaceuticals.
A number of equities research analysts have recently weighed in on the stock. BidaskClub upgraded shares of Deciphera Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, December 1st. Zacks Investment Research upgraded shares of Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $27.00 price target for the company in a research report on Tuesday, January 8th. Leerink Swann lowered their price objective on shares of Deciphera Pharmaceuticals from $28.00 to $20.00 and set an “underperform” rating for the company in a research report on Friday, November 16th. Cantor Fitzgerald restated a “buy” rating and set a $53.00 price objective on shares of Deciphera Pharmaceuticals in a research report on Thursday, December 20th. Finally, B. Riley downgraded shares of Deciphera Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Tuesday, January 1st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $42.67.
In other Deciphera Pharmaceuticals news, insider Daniel Lee Flynn sold 152,629 shares of the business’s stock in a transaction on Wednesday, January 16th. The shares were sold at an average price of $26.00, for a total transaction of $3,968,354.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Thomas Patrick Kelly sold 5,000 shares of the business’s stock in a transaction on Monday, January 7th. The stock was sold at an average price of $25.18, for a total transaction of $125,900.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 198,426 shares of company stock valued at $5,247,846. Company insiders own 20.61% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Legal & General Group Plc grew its stake in shares of Deciphera Pharmaceuticals by 55.4% during the third quarter. Legal & General Group Plc now owns 1,647 shares of the company’s stock worth $64,000 after buying an additional 587 shares during the last quarter. Great West Life Assurance Co. Can bought a new stake in shares of Deciphera Pharmaceuticals during the fourth quarter worth $50,000. Bank of America Corp DE grew its stake in shares of Deciphera Pharmaceuticals by 316.1% during the second quarter. Bank of America Corp DE now owns 2,609 shares of the company’s stock worth $103,000 after buying an additional 1,982 shares during the last quarter. MetLife Investment Advisors LLC bought a new stake in shares of Deciphera Pharmaceuticals during the third quarter worth $235,000. Finally, Rhumbline Advisers grew its stake in shares of Deciphera Pharmaceuticals by 53.6% during the fourth quarter. Rhumbline Advisers now owns 11,466 shares of the company’s stock worth $241,000 after buying an additional 4,000 shares during the last quarter. 57.28% of the stock is currently owned by hedge funds and other institutional investors.
Deciphera Pharmaceuticals Company Profile
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.
Featured Story: Capital Gains
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.